IQVIA uses advanced analytics and innovative technology, to find
medium-to-high rates of flu in multiple U.S. markets; highest levels in
parts of Montana, Nebraska and Texas

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA™
(NYSE:IQV), a leader in human data science, provides consumers with
quick and easy access to seasonal suffering data, giving them unique
insights into important health related information. Recent data show
that flu season is hitting hard in several key markets.

IQVIA monitors seasonal suffering across the U.S. and provides key
healthcare measurements for flu, allergy, and cough and cold season.
Powered by the IQVIA CORE™, unparalleled data and advanced analytics
capabilities, IQVIA provides detailed information on levels of impact,
identification of most affected U.S. cities, and a breakdown between
pediatric and adult populations in each market.

IQVIA’s proprietary platform, www.FluSTAR.com,
provides cold and flu forecast information for every ZIP code in the
country. FluSTAR allows health care professionals and consumers to see
the most up-to-date information on the spread of the flu during each
influenza season. Data are gathered through different surveillance
methods including rapid assay data, laboratory confirmation, and
clinical diagnosis data. This surveillance allows a regional and
national picture of influenza activity to be generated.

As of mid-February, FluSTAR indicated medium-high or high rates of flu
in multiple markets throughout the country with the highest levels
captured in Southwest Montana, Western Nebraska and in Del Rio, Texas.
Nationally, flu numbers continued to rise throughout February and in
March flu numbers should decline to the early February numbers.

“IQVIA’s unparalleled data gives us the ability to monitor seasonal
suffering across the U.S.,” said Chris Nickum, vice president, general
manager, Primary Intelligence at IQVIA. “We are able to track and
forecast the cold, flu, and allergy season with a high degree of
accuracy.”

IQVIA also provides asthma and allergy information at www.AsthmaForecast.com.
This includes the four-day Asthma Forecast and daily Air Quality Index
which are available for every U.S. ZIP code. This free online resource
also provides access to current asthma news, as well as two years of
archived asthma-related articles.

IQVIA’s proprietary platform at www.Pollen.com
provides daily allergy severity forecasts that show upcoming airborne
allergen conditions by ZIP code. IQVIA developed Pollen.com’s
proprietary forecasts and manufactures Rotorod® the leading tool for
pollen count measurement. Rotorod has been used to collect pollen across
the country for over 30 years.

About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of
advanced analytics, technology solutions and contract research services
to the life sciences industry. Formed through the merger of IMS Health
and Quintiles, IQVIA applies human data science — leveraging the
analytic rigor and clarity of data science to the ever-expanding scope
of human science — to enable companies to reimagine and develop new
approaches to clinical development and commercialization, speed
innovation and accelerate improvements in healthcare outcomes. Powered
by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the
intersection of large-scale analytics, transformative technology and
extensive domain expertise, as well as execution capabilities. With more
than 58,000 employees, IQVIA conducts operations in more than 100
countries.

IQVIA is a global leader in protecting individual patient privacy. The
company uses a wide variety of privacy-enhancing technologies and
safeguards to protect individual privacy while generating and analyzing
information on a scale that helps healthcare stakeholders identify
disease patterns and correlate with the precise treatment path and
therapy needed for better outcomes. IQVIA’s insights and execution
capabilities help biotech, medical device and pharmaceutical companies,
medical researchers, government agencies, payers and other healthcare
stakeholders tap into a deeper understanding of diseases, human
behaviors and scientific advances, in an effort to advance their path
toward cures. To learn more, visit www.iqvia.com.

Click
here to subscribe to Mobile Alerts for IQVIA.

Contacts

Tor Constantino, IQVIA Media Relations ([email protected])
+1.484.567.6732

Andrew Markwick, IQVIA Investor Relations ([email protected])
+1.973.257.7144